Jonathan Wolleben
Stock Analyst at JMP Securities
(4.51)
# 321
Out of 5,022 analysts
227
Total ratings
54.22%
Success rate
21.18%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $20 → $29 | $11.23 | +158.24% | 18 | Oct 1, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $86 → $143 | $44.05 | +224.63% | 16 | Sep 26, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $135 → $142 | $105.20 | +34.98% | 5 | Sep 25, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $27 → $28 | $11.54 | +142.63% | 5 | Sep 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $483 → $485 | $437.10 | +10.96% | 13 | Aug 20, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Market Outperform | $18 | $3.90 | +361.54% | 13 | Aug 19, 2025 | |
| PHVS Pharvaris | Maintains: Market Outperform | $55 → $52 | $20.96 | +148.09% | 12 | Aug 13, 2025 | |
| ATXS Astria Therapeutics | Maintains: Market Outperform | $25 → $26 | $11.61 | +123.94% | 3 | Aug 13, 2025 | |
| QNCX Quince Therapeutics | Maintains: Market Outperform | $9 → $8 | $1.94 | +312.37% | 2 | Aug 12, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $67 → $69 | $76.94 | -10.32% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $79 → $81 | $73.28 | +10.53% | 11 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $89 → $87 | $30.13 | +188.75% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $15 | $3.97 | +277.83% | 13 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.46 | +225.20% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $15.65 | +34.19% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.52 | +886.84% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.16 | +208.44% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $4.15 | +1,709.41% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $13.52 | +181.07% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $6.42 | +180.37% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.38 | +166.27% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $43.02 | +16.23% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $75.73 | +18.84% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $122.89 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $225 | $176.91 | +27.18% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $683.51 | -29.04% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $7.51 | +326.10% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.53 | +1,395.89% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $32.58 | -26.34% | 1 | May 12, 2023 |
Ocular Therapeutix
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $11.23
Upside: +158.24%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Market Outperform
Price Target: $86 → $143
Current: $44.05
Upside: +224.63%
Rhythm Pharmaceuticals
Sep 25, 2025
Maintains: Market Outperform
Price Target: $135 → $142
Current: $105.20
Upside: +34.98%
KalVista Pharmaceuticals
Sep 12, 2025
Maintains: Market Outperform
Price Target: $27 → $28
Current: $11.54
Upside: +142.63%
Madrigal Pharmaceuticals
Aug 20, 2025
Maintains: Market Outperform
Price Target: $483 → $485
Current: $437.10
Upside: +10.96%
Larimar Therapeutics
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.90
Upside: +361.54%
Pharvaris
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $20.96
Upside: +148.09%
Astria Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $25 → $26
Current: $11.61
Upside: +123.94%
Quince Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.94
Upside: +312.37%
Protagonist Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $76.94
Upside: -10.32%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $79 → $81
Current: $73.28
Upside: +10.53%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $30.13
Upside: +188.75%
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.97
Upside: +277.83%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.46
Upside: +225.20%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $15.65
Upside: +34.19%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.52
Upside: +886.84%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.16
Upside: +208.44%
May 16, 2025
Reiterates: Market Outperform
Price Target: $75
Current: $4.15
Upside: +1,709.41%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $13.52
Upside: +181.07%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $6.42
Upside: +180.37%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.38
Upside: +166.27%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $43.02
Upside: +16.23%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $75.73
Upside: +18.84%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $122.89
Upside: -
Dec 11, 2024
Downgrades: Market Perform
Price Target: $225
Current: $176.91
Upside: +27.18%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $683.51
Upside: -29.04%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $7.51
Upside: +326.10%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.53
Upside: +1,395.89%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $32.58
Upside: -26.34%